Xi Yang

Xi Yang

Auto-generated profile, based on publicly available information

Xi Yang

Department of Medicine, Division of General Internal Medicine University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in Cancer Medicine
Verified
Journal Article
Open access
XYXi Yang
Xi Yang
LKLilit Karapetyan
Lilit Karapetyan
ZHZiyu Huang
Ziyu Huang
AKAndrew D. Knight
Andrew D. Knight
SRSneha Rajendran
Sneha Rajendran
John M. KirkwoodJohn M. Kirkwood
John M. Kirkwood
Background: Multiple primary melanoma (MPM) is known to be associated with familial melanoma. However, the association between MPM and other personal and familial cancers is not well documented. The objective of this study was to evaluate the association between MPM and personal history of other cancers or cancer history among first‐degree relatives (FDRs).Methods: We performed a retrospective case–control study including cases with gender‐matched MPM and single primary melanoma (SPM) at a 1:2 ratio from the University of Pittsburgh Cancer Institute Melanoma Center Biological Sample and Nevus Bank. The associations between MPM and other cancers were evaluated using univariable and multivariable logistic regression models.Results: In total, 378 patients (44.2% men; median age 52 years) were enrolled, including 252 with SPM and 126 with MPM. In comparison to patients with SPM, patients with MPM were more likely to have squamous cell carcinoma (odds ratio [OR] 1.95, 95% confidence interval [CI] 1.001–3.79, p = 0.047) and prostate cancer (OR 2.72, 95% CI 1.07–7.01, p = 0.034). FDRs of patients with MPM had higher prevalence of melanoma (OR 2.37, 95% CI 1.31–4.28, p = 0.004) and prostate cancer (OR 2.92, 95% CI 1.47–6.14, p = 0.002) but not other cancers. In multivariable analysis, the association remained significant between MPM and squamous cell carcinoma (OR 2.18, 95% CI 1.08–4.39, p = 0.028), prostate cancer (OR 2.85, 95% CI 1.09–7.54, p = 0.032), FDR history of melanoma (OR 2.37, 95% CI 1.31–4.29, p = 0.004), and FDR history of prostate cancer (OR 3.26, 95% CI 1.59–6.83, p = 0.001).Conclusions: Patients with MPM have a higher prevalence of personal and FDR histories of nonmelanoma skin cancers and prostate cancer.

21 June 2022 in Haemophilia
Verified
Journal Article
Closed access
XYXi Yang
Xi Yang
KJKwonho Jeong
Kwonho Jeong
JYJonathan G. Yabes
Jonathan G. Yabes
MRMargaret V. Ragni
Margaret V. Ragni

23 March 2022 in Cancer
Verified
Journal Article
Closed access
LKLilit Karapetyan
Lilit Karapetyan
XYXi Yang
Xi Yang
AKAndrew D. Knight
Andrew D. Knight
ZHZiyu Huang
Ziyu Huang
HWHong Wang
Hong Wang
John M. KirkwoodJohn M. Kirkwood
John M. Kirkwood

10 November 2026 in Blood Advances
Verified
Journal Article
Closed access
XYXi Yang
Xi Yang
HDHenry Dumke
Henry Dumke
STSwetha Thiruvengadam
Swetha Thiruvengadam
CAChristine Argao
Christine Argao
JSJoseph G. Schroers-Martin
Joseph G. Schroers-Martin
YKYasmin Karimi
Yasmin Karimi
Primary mediastinal B-cell lymphoma (PMBCL) is a rare form of large B-cell lymphoma (LBCL), with ∼90% of patients cured with frontline treatment. For relapsed or refractory (R/R) disease, the optimal treatment is unclear. CD19 chimeric antigen receptor T-cell (CAR T) therapy has been established as the preferred second-line (2L) treatment for primary refractory or early-relapsing LBCL based on the overall survival benefits observed in landmark phase 3 trials. However, patients with PMBCL were underrepresented in these pivotal studies. This study evaluated outcomes of 252 patients treated with 2L therapies for R/R PMBCL at 14 US institutions between 2001 and 2025. Platinum-based salvage therapy with intent to proceed to high-dose therapy and autologous stem cell transplant (HDT/ASCT; platinum cohort) and CD19 CAR T therapy (CAR T cohort) were given as 2L therapies in the real-world setting in 157 and 26 patients, respectively. Overall response rate (ORR), complete response (CR) rate, and median progression-free survival (PFS) were significantly higher in the CAR T cohort compared with the platinum cohort (ORR, 91.3% vs 44.2%; P< .001; CR, 65.2% vs 14.7%; P< .001; median PFS, not reached vs 3.5 months; hazard ratio, 0.28; 95% confidence interval, 0.15-0.54; P = .001). No significant difference was observed in overall survival. This study demonstrated the superior response rate and PFS of CD19 CAR T therapy over platinum-based salvage therapy with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.